Imaging metastatic bone disease from carcinoma of the prostate by Messiou, C et al.
Minireview
Imaging metastatic bone disease from carcinoma of the prostate
C Messiou*,1, G Cook
2 and NM deSouza
1
1Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs
Road, Surrey SM2 5PT, UK;
2Department of Nuclear Medicine, Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK
Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the
conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment
response, particularly because of a ‘flare’ phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment,
and newer techniques allow quantitation. In addition to
18F-fluorodeoxyglucose (
18FDG), newer PET isotopes are also showing
promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic
bony metastases, and links them to the underlying pathological changes within bone lesions.
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Prostate cancer is the second most common cancer in men,
accounting for 1 in 9 of all new cancers, and with more than
670000 new diagnoses annually worldwide. The metastatic spread
is primarily in the skeleton (supporting the ‘seed-and-soil’
hypothesis described by Paget in 1889) in which lesions are often
located in vertebra and ribs because of dissemination through
Batson’s venous plexus. The spread in bone also follows the
distribution of adult red bone marrow, that is, skull, thorax, pelvis,
spine, proximal long bones (Imbriaco et al, 1998; Scher, 2003),
subsequently progressing to involve adjacent cortical bone.
Preclinical models confirm that skeletal sites rich in cellular
marrow with active turnover show increased cancer localisation
(Schneider et al, 2005). Although predominantly osteoblastic,
osteoclast activation also has an important role in the growth of
sclerotic metastases in the bone. In a study of 68 men with
prostatic bone metastases who underwent surgery for stabilisation
of pathological fracture or impending fracture, most metastases
were osteoblastic, but 29.1% had metastases that were osteolytic or
mixed (Cheville et al, 2002).
Skeletal metastases occur in approximately 90% of patients
presenting with advanced prostate cancer, and the burden of bone
disease directly correlates with survival (Cooper et al, 2003, Carlin
and Andriole, 2000). After treatment of the primary site, bone is
the first site of relapse in more than 80% of cases (Clamp et al,
2004). Plain film and bone scintigraphy studies form the mainstay
of detection, but they underestimate true incidence. In one autopsy
series of 1589 men with prostate cancer (47% were unsuspected),
the incidence of metastatic bone disease was 90% (Bubendorf et al,
2000).
The detection of bone metastases indicates progression to lethal
prostate carcinoma (Scher, 2003). At this stage, complete
remissions are rare and onset of the complications of bone
metastases are likely (Clamp et al, 2004). The investigation of
therapeutic interventions to slow the progression of bone disease
and its complications make the need for accurate assessment of
disease burden in the bone and its response to treatment of
fundamental importance. PSA is used widely to monitor response
to therapy, with a decrease in PSA to the normal range after
treatment used as a predictor of prolonged response in many
patients (Ruckle et al, 1994). However, PSA levels are influenced by
both soft tissue and bony disease and PSA does not always
correlate with tumour burden.
Imaging bone disease in prostate carcinoma frequently involves
a cascade of studies that start with Tc
99m methylene diphosphonate
(Tc
99mMDP) bone scintigraphy, backed up by plain film correla-
tion and followed by magnetic resonance imaging (MRI),
computerised tomography (CT) or even positron emission
tomography (PET)/CT. The implications of this multistep
approach involve patient time, imaging time, costs and radiation
dose. Validation of imaging biomarkers for bone derived from
these studies has been hindered by a lack of a gold standard, as
histological verification is not appropriate. Previous arguments
that MRI is too costly and time consuming need to be revisited,
particularly in the setting of its increased availability, and with the
development of functional imaging approaches. Currently, the
assessment of therapeutic response in clinical trials relies solely
on qualitative assessment on bone scintigraphy, as Response
Evaluation Criteria In Solid Tumours (RECIST) criteria classify
osteoblastic bone metastases as non measurable (Eisenhauer et al,
2009). This article reviews the characteristics of prostate bone
metastases recognised with various imaging techniques in the
context of their pathogenesis and explores the potential of these
techniques for assessing tumour burden and response to therapy.
BONE SCINTIGRAPHY IN ASSESSMENT OF BONE
METASTASES
The popularity of bone scintigraphy arose from its comparisons
with plain film radiography. Bone scintigraphy can detect a 10%
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www.bjcancer.comchange in bone mineral turnover, whereas the bone must
demineralise by 50% before a lesion is detected by plain film. It
can also detect bone metastases up to 18 months before plain film
reveals them (Taoka et al, 2001). However, because bone
scintigraphy images the secondary effects of the tumour on the
skeleton, false positives occur from degenerative change, inflam-
mation, Paget’s disease and trauma (Figure 1). The osteoblastic
response that occurs as a result of bone healing/flare response can
also lead to a false-positive diagnosis of disease progression.
The sensitivities and specificities for detection of bone metastases
by MDP bone scintigraphy have sometimes been quoted, but the
absence of a histological gold standard means that these are not
sensitivities and specificities in the true sense. Comparators vary
from study to study, but PSA, soft tissue disease, follow-up and
other imaging modalities are often used as a gold standard, all with
their own limitations.
The flare phenomenon on radionuclide bone scan in patients
with prostate cancer has been reported at anywhere between 6 and
25% and is also a feature observed on plain film. It may be because
of an increase in blood flow caused by an inflammatory response
or an increased turnover of hydroxyapatite in the new bone laid
down as part of the healing process. In prostate cancer, if the scan
taken 3 months after introduction of therapy shows worsening of
disease, there is a high probability that this is real. If, however, the
patients’ clinical parameters indicate a response, then flare should
be considered. A follow-up scan at 6 months can resolve the issue
(Figure 2) (Levenson et al, 1983; Pollen et al, 1984).
Regardless of the flare phenomenon, the sensitivity of bone
scintigraphy in detecting a response to therapy remains question-
able; metastases showed by bone scintigraphy have been shown to
remain stable despite other parameters indicating a response
(Scher, 2003). Coombes et al (1983) found purely sclerotic bone
metastases impossible to assess on bone scintigraphy, as increased
sclerosis without scintigraphic changes occurred in the responding
and non-responding patients. In the responding patients (as
judged by disease in non-osseous sites), any detectable response
on bone scan is often delayed by up to 6–8 months and it can take
over 2 years for complete resolution of bone scintigraphy findings
(Scher, 2003), even when all of the disease has been eliminated
from the bone. Conversely, a stable positive scintigraphic lesion, in
conjunction with a fading sclerotic lesion on radiographs in a
positive scintigraphic lesion, can be a sign of progression (Pollen
et al, 1984). A further source of debate is the occurrence of a new
lesion on bone scintigraphy. Previously, this was thought to rule
out flare response but it has been shown that appearance of a new
lesion on bone scans or plain film within 6 months of initiation of
therapy can be a part of the flare response as a result of the healing
of previously occult lesions (Ciray et al, 2005).
Descriptive reports provided by bone scintigraphy, although
useful for diagnosis, are limited when assessing the response to
therapy, in which more quantitative information is desirable. The
Bone Scan Index proposed by Imbriaco et al, which quantifies the
proportion of the skeleton involved by tumour as well as the
distribution of disease, has not been widely adopted. Other
proposals include an automated assessment of the percentage of
involvement by metastatic bone disease on bone scintigraphy to
monitor response to therapy. Although scoring systems of this
type may relate to prognosis and response to therapy, they can be
Figure 1 False-positive MDP bone scintigraphy. A male patient with
prostate cancer and left sided sacral pain previously treated with IMRT, PSA
o0.04. MDP bone scintigraphy (posterior view, A) showed a solitary focal
area of uptake in the left side of the sacrum (arrow), interpreted as a bone
metastasis. Symptom progression with bilateral sacral pain but PSA
remaining o0.04 prompted an MRI, which showed bilateral oedema in
the sacral ala (T1W coronal), (B) and a fracture through S2 (arrow) but no
evidence of metastasis.
Figure 2 Flare response on MDP bone scintigraphy: metastatic disease in the inferior pubic rami (arrows, A) showed increased uptake 3 months after
chemotherapy (B) that diminished at 6 months (C).
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2003). Other limiting factors are the lack of anatomical detail.
Combined single-photon emission computerised tomography
(SPECT) and X-ray CT improve anatomical detail and reduce the
number of equivocal lesions detected on bone scintigraphy (Even-
Sapir et al, 2006). Bone scintigraphy therefore does have a role in
the assessment of prostatic bone metastases but should not be used
in isolation when considering response to therapy.
MRI FOR ASSESSMENT OF BONE METASTASES
Magnetic resonance imaging is potentially the technique of
choice in evaluating prostate bone metastases as it is sensitive to
early changes in bone marrow that precede the osteoblastic
response in the bone matrix. Metastasis to bone marrow leads
to a lengthened T1 relaxation time and signal loss, which
contrasts with the surrounding high signal marrow fat. The
conspicuity of bone metastases can sometimes be increased by T2-
weighted fat-suppressed sequences such as short tau inversion
recovery (STIR).
Magnetic resonance has been shown to detect bone metastases
in 37.5% of patients with negative or inconclusive bone scan and
plain films, and one prospective study indicates sensitivities and
specificities of 100 and 88% for MRI and 46 and 32% for bone
scintigraphy (Lecouvet et al, 2007). The discrepancy between these
modalities arises because even with extensive marrow involvement
by metastases, the amount of bony matrix destroyed is small
(Taoka et al, 2001). In particular, vertebral bodies have a large
medullary cavity, and hence the cortical involvement leading to
positive bone scintigraphy occurs late (Taoka et al, 2001).
Furthermore, tumour cells may reside between trabeculae in
which they may be recognised on MR but not on bone scintigraphy
or plain film (Figure 3) (Yamaguchi et al, 1996). In one study, all
intramedullary lesions on MRI were negative on bone scintigraphy
regardless of size; once there was a cortical involvement, bone
scans were likely to be positive. Positive bone scan findings were
always associated with MRI evidence of cortical involvement. In
addition, transcortical lesions had a higher incidence of positive
bone scan findings than subcortical lesions in which lesion
detection was shown to be size dependant (Taoka et al, 2001).
Although the comparisons have been carried out without SPECT, it
is unlikely to have an affect on those cases in which disease is
confined to the medullary cavity. Interobserver agreement is also
greater in MR studies than in bone scintigraphy (Algra et al, 1991).
The RECIST criteria applied to MRI of the axial skeleton in one
small study have confirmed the superior sensitivity of MRI to bone
scintigraphy in the detection of bone metastases and have shown
that it may have a role in quantitatively following bone metastases.
Despite classifying diffuse bone involvement as non-measurable
because it was impossible to obtain longest axis dimensions, this
study increased the number of patients with ‘measurable’
metastatic lesions by 29% (Tombal et al, 2005).
Although conventional MRI lacks whole-body coverage, it is
possible to cover the whole spine and pelvis (in which the majority
of prostate cancer metastases arise) in minutes and to include the
femoral necks that are at risk of pathological fracture. A study of
66 patients with high-risk prostate cancer has shown no cases of
isolated peripheral metastases (Lecouvet et al, 2007). With newer
scanners, coverage of the whole skeleton with MRI by use of
whole-body coil arrays or moving table arrangements is possible
but it is time consuming, and the difficulty with MR interpretation
of certain areas, such as ribs, does not make such intensive
imaging worthwhile.
Intertrabecular tumour. Tumour (grey)
seeded in bone marrow with no effect on
trabeculae (white). MR shows diffuse signal
change on T1W imaging. Bone scintigraphy
would appear normal. Depending on tumour
burden this may be detected on 18FDG PET.
Focus of clustered tumour cells, no
effect on trabeculae. MR shows a focus of
signal loss on T1W imaging (arrow). Bone
scintigraphy and 18F-Fluoride PET would
appear normal. Depending on tumour
burden this may be detected on 18FDG PET.
Osteoblastic reaction to tumour cells
with thickened trabeculae. MR shows
marked signal loss on T1W imaging (*).
Bone scintigraphy and 18F-Fluoride PET
would appear abnormal when a significant
volume of osteoblastic reaction has taken
place. The osteoblastic reaction may
obscure any 18FDG uptake in PET studies.
*
*
Figure 3 Schematic describing the relationship between patterns of tumour seeding in bone marrow and imaging findings.
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assessment of bone metastases. Dynamic contrast-enhanced MRI
provides information on the perfusion and permeability of
tumours and has shown potential in detecting metastatic bone
disease and monitoring response to therapy (Montemurro et al,
2004). Diffusion-weighted imaging (DWI) can detect differences in
water diffusion between tissues, which can be measured as
apparent diffusion coefficients (ADC). Thus, DWI can be used to
record the restriction of water in and around tumour cells and
changes in water diffusion that occur as a result of changes in
cellular density and membrane integrity after therapy (Charles-
Edwards and deSouza, 2006). Although DWI has been validated in
several soft tissue tumours (Montemurro et al, 2004), its use in
metastatic bone disease is in its infancy. In fact, mature bone
marrow is particularly amenable to interrogation with DWI,
because its high fat content results in a significant diffusion
restriction. When diffusion-restricted fatty marrow is replaced
with water containing tumour cells, these foci become conspicuous
as areas of increased diffusivity. This generates excellent contrast
between normal marrow and tumour. The derived ADC maps
allow quantitative assessment of changes in cellularity in response
to therapy (Figure 4). Furthermore, recent hardware and software
advances have led to whole-body DWI assessment of the skeleton
in very reasonable timeframes, and anatomic images can be fused
to allow assessment of threat to spinal cord or nerve roots.
Preliminary data suggest that DWI may surpass conventional T1W
imaging and STIR for lesion detection (Figure 5) and is equally as
effective as
11C choline (Luboldt et al, 2008).
Magnetic resonance spectroscopy has also been used to
differentiate malignant from benign bone tumours. Interrogating
choline metabolites on
1H MRS or phosphomonoesters on
31PM R
spectroscopy in small studies has shown some success (Sijens et al,
1997; Wang et al, 2004). However, both techniques are limited to
large and relatively superficial lesions and are extremely time
intensive and have limited anatomical coverage.
PET FOR ASSESSMENT OF BONE METASTASES
The limitations of bone scintigraphy have spurred an interest in
PET imaging in prostatic bone metastases.
18F-fluorodeoxyglucose
(
18FDG) is a non-specific tracer. It is an analogue of glucose,
thereby reflecting metabolism and detecting the increased glucose
transport and glycolysis associated with several tumour types. It
gains entry into cells by membrane transporter proteins such as
Glut1, which are expressed in many tumours. It is phosphorylated
intracellularly to FDG-6-phosphate and retained within malignant
cells. Tumour hypoxia may also increase
18FDG accumulation
through activation of glycolysis. The quantitative parameter used
is typically a standardised uptake value (SUV), which represents
the tissue activity within a region of interest corrected for the
injected activity and for the patients’ body weight. Sclerotic
metastases show little
18FDG uptake compared with lytic lesions
(Fogelman et al, 2005). The exact cause for this reduced uptake is
not known but speculation centres on lower volumes of tumour
associated with sclerotic metastases, a difference in sclerotic tissue
metabolism or attenuation of photons by densely calcified tissues.
18FDG PET is therefore less sensitive than MDP bone scintigraphy
in the identification of sclerotic metastases (Shreve et al, 1996) and
had been shown to detect only 18% of sites seen on bone
scintigraphy in patients with stable or responding disease. The
lesions not detected by
18FDG PET are often those that are stable
on follow-up bone scintigraphy (Morris et al, 2002). However,
some lesions detected on
18FDG PET alone become positive on
bone scintigraphy after some time. It is likely therefore that
18FDG
PET is detecting active disease within bone marrow before a
significant secondary bone reaction or cortical involvement. A new
lesion or a rise in SUV within a lesion that is correlated with a rise
in PSA indicates disease progression, and Morris et al (2005) have
shown that
18FDG PET is very promising as an outcome measure
for prostate cancer.
Even without CT correlation,
18FDG PET offers superior
resolution to conventional gamma camera imaging, and the
acquisition of tomographic images is routine. The combination
with CT on hybrid PET/CT scanners offers the advantage of fusing
structural and functional data. The concordant lesions found on
both PET and CT are highly likely to represent bone metastases;
however, this likelihood falls if only the PET is positive and is
reduced even further if the lesion is solitary. Solitary lesions
positive on PET but not on CT should be interpreted with caution.
Lesions seen on CT but not on
18FDG PET have an even lower
positive predictive value (Taira et al, 2007).
Figure 4 A male patient with prostate cancer metastases to bone. T1W axial MRI pelvis (A) shows a metastasis within the right iliac bone (arrow). High
signal within the lesion on the diffusion-weighted MRI of the pelvis (B) indicates that diffusion within the metastasis is less restricted than diffusion in the
surrounding normal marrow. An apparent diffusion coefficient (ADC) map of pelvis (C) generated from the diffusion-weighted imaging data (B values 0, 50,
100, 250 500, and 750) provides a quantitative index of water diffusion within the tumour. The ADC map also shows heterogeneity of water diffusion within
the tumour not shown by conventional T1W imaging.
Imaging prostatic bony metastases
C Messiou et al
1228
British Journal of Cancer (2009) 101(8), 1225–1232 & 2009 Cancer Research UKAnother non-specific bone PET tracer
18F-fluoride (half-life
110min) is taken up by bone metastases and related to their
osteoblastic activity. Diffusion of
18F-fluoride through capillaries
into bone leads to fluoroapatite formation. This is stored on the
bone surface in which turnover is the greatest. As the first pass
extraction of
18F into bone is almost 100% (compared with 64% for
the larger phosphate complexes used in traditional bone scinti-
graphy),
18F-fluoride PET shows a high contrast between normal
and abnormal bone (Figure 6) (Langsteger et al, 2006). It is thus an
attractive imaging agent with high-quality images that are likely to
be more sensitive than conventional bone scintigraphy for
detecting both osteoblastic and osteolytic bone metastases. The
earlier detection of osteoblastic activity by
18F-fluoride PET than
with MDP bone scintigraphy (Even-Sapir et al, 2006) is further
enhanced by the increased spatial resolution of PET imaging that
increases the sensitivity of the technique. Specificity problems with
18F-fluoride PET are similar to those encountered with traditional
MDP bone scintigraphy, although the improved spatial resolution
and the combination with CT helps to differentiate between benign
and malignant processes in equivocal cases by clarifying the exact
anatomical location of a lesion within a bone, for example,
vertebral body or end plate (Even-Sapir et al, 2006). A combined
18F-fluoride and FDG PET examination has been proposed by
some researchers (Hara et al, 1998), offering the attractive
prospect of additive information from osteoblastic and metabolic
activity.
Other PET tracers currently under evaluation include
11C
methionine and
11C/
18F-choline and
11C-acetate derivatives. The
interest in choline has grown from evidence that it is transported
into cells, phosphorylated and thus trapped within cells and used
for the synthesis of phospholipids. Malignant cells have elevated
levels of choline and upregulation of choline kinase activity as a
result of increased cell turnover.
18F-choline PET/CT has shown
the potential to both upstage and downstage bone disease in
prostate cancer when compared with Tc
99mMDP bone scintigraphy.
It has a longer half-life (110min) with slightly better imaging
quality than
11C-choline (half-life 20min) imaging but excretion
into urine interferes with pelvic imaging. As with
18F-FDG, there is
some evidence to suggest reduced uptake in patients treated with
antiandrogen therapy (Langsteger et al, 2006).
11C-choline PET
may have other advantages over
18F-FDG PET for detection of
pelvic disease and bone metastases. Pelvic imaging is made easier
as its urinary excretion is negligible. However,
11C-choline does
accumulate in liver, kidney, spleen and pancreas, making
assessment of the upper abdomen difficult (Hara et al, 1998).
The short half-life of 20min limits its use to sites with cyclotrons.
Most studies of choline in prostate cancer have interrogated
localised or nodal disease. In one retrospective analysis,
11C-choline PET/CT was valuable in the assessment of metastatic
bone disease in terms of detection, localisation and characterisa-
tion (Tuncel et al, 2008).
11C-acetate also shows marked uptake in
prostate cancer and has been shown to be more sensitive in
detection of prostate cancer than
18FDG PET, but there are limited
data on bone metastases (Oyama et al, 2002). Tracers targeted to
prostate-specific membrane antigen and androgen receptor
expression are also of increasing interest as response biomarkers
(Apolo et al, 2008). However, as with many of the promising
tracers for imaging metastatic prostate cancer, their role within
clinical practice and clinical trials remains to be established within
large prospective studies.
CONCLUSION
In determining which diagnostic test should be used in the
evaluation of bony metastases in prostate cancer, it is important to
recognise that there are distinct patient groups for whom imaging
objectives differ (Figure 7).
For patients embarking on radical therapy, the exclusion of bone
metastases is paramount, making it imperative to use the most
sensitive and specific diagnostic test available – currently this is
MRI, which also evaluates potential threat to the spinal cord and
nerve roots (evidence from prospective trials is summarised in
Table 1). Future development may see MR imaging of the pelvis
and whole spine as a baseline staging examination. Arguments that
cost and availability limit its use may dwindle as the installed
scanner base increases and faster imaging techniques are
developed. As PET/CT procurement in the United Kingdom
advances,
18F-fluoride PET/CT will challenge MRI as a diagnostic
test for bone metastases in this setting, with its reported sensitivity
and specificity of 100% (Even-Sapir et al, 2006). Further
prospective studies comparing whole-body MRI and
18F-fluoride
PET/CT, including cost analyses, should be encouraged.
Figure 5 Comparison of MRI and MDP bone scintigraphy: pelvic T1W MRI (A) and b750 DWI (B) of a patient with carcinoma of the prostate shows a
new small metastasis (arrows) involving the left neck of femur. This small intramedullary lesion has not evoked enough osteoblastic reaction to become
visible on bone scintigraphy (C).
Figure 6 Comparison of
18F-fluoride PET and MDP bone scintigraphy.
(A)
18F-fluoride shows an increased number of metastatic deposits and
better resolution than MDP bone scintigraphy (B) on the same patient.
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chemotherapy, bone scintigraphy in conjunction with PSA are
adequate markers of bone disease status. In cases in which there
are symptoms/signs of neurological compromise, MRI is of course
the test of choice.
Early clinical trials require a robust and timely quantitative
marker of disease response. In addition, given the extremely high
incidence of metastatic bone disease in patients with carcinoma of
the prostate entering clinical trials, impending cord compression
should be identified with MRI and appropriate local treatment
arranged if necessary. Further, the high sensitivity of MRI for
lesion detection and capability for tumour dimension measure-
ment can then be applied as an assessment of response to
treatment (Tombal et al, 2005). Ultimately, the future may be
with PET/MR – wide anatomical coverage and assessment of
spinal cord and fusion of anatomical and quantitative data of
tissue microarchitecture (DWI) with function from tracers such as
choline or fluoride. At present, clinical trials demand a multi-
parametric approach with preliminary evidence, indicating that
DWI should be pursued as a biomarker of metastatic bone disease.
Patients with symptoms /
signs of cord / nerve root
compression
Patients at high risk planned for radical
treatment and patients with rising PSA post
therapy  
Patients planned for first line
hormone therapy or first
line chemotherapy
Equivocal 
Benign pathology –
reassuring
Bone metastases confirmed
Normal
Patients entering clinical trials especially early
trials where efficacy is unknown or trials
where a placebo may be given
Nuclear Medicine :
18F Fluoride       –   osteoblast  activity
18
FDG PET/CT    –   glucose metabolism 
                                  
Choline tracers –   cell turnover
Disease specific  -   ie PSA antigen targets
MDP bone scintigraphy has decreasing utility in this setting: non
quantitative, response can be delayed by months, susceptible to
flare response, no assessment of threat to spinal cord.
Conventional MRI :
Bone marrow
+/- DWI :bone marrow + tissue
microarchitecture
Tc99mMDP bone scintigraphy :
osteoblast activity
Plain film: cortical bone
Rising PSA, normal
bone scan
Figure 7 Flow chart showing decision pathways for imaging metastatic bone disease in patients with carcinoma of the prostate. Experimental/non-
validated techniques are in italics.
Table 1 Detection of metastatic bone disease from carcinoma of the prostate: summary of prospective studies over the past 10 years
Imaging
modality
Structure/
mechanism
measured Reference Patients Gold standard used
Sensitivity
(%)
Specificity
(%)
Planar MDP bone
scintigraphy
Osteoblast
activity
Lecouvet et al (2007) 66 Consensus decision using bone scintigraphy, CT, MRI,
follow-up, clinical and serum markers
46 32
Even-Sapir et al (2006) 44 Consensus decision using
18F-fluoride PET/CT, and follow-
up
69 64
SPECT Even-Sapir et al (2006) 20 Consensus decision using
18F-fluoride PET/CT, and follow-
up
92 82
MRI Bone marrow Lecouvet et al (2007) 66 Consensus decision using F/U bone scintigraphy, CT, MRI
and clinical and serum markers
100 88
DW MRI Bone marrow
microstructure
Luboldt et al (2008) 11
11C-choline used as gold standard. In all, 15 true-positive
bone metastases were identified by DWI, 15 by STIR and
14 true positives identified on T1W imaging
NA NA
18FDG PET Glucose
metabolism
Morris et al (2002) 17 Consensus decision using bone scintigraphy. In all, 71%
lesions visible on both modalities, 23% only on bone scan
and 6% only on FDG PET
NA NA
Shreve et al (1996) 22 Consensus decision using bone scintigraphy and follow-up 65
18F-fluoride
PET/CT
Osteoblast
activity
Even-Sapir et al (2006) 44 Consensus decision using bone scintigraphy and follow-up 100 100
Beheshti et al (2008) 38 Consensus decision using
18F-fluorocholine PET/CT and
follow-up
81 93
18F-fluorocholine
PET/CT
Bone marrow –
cellularity
Beheshti et al (2008) 38 Consensus decision using
18F-fluoride PET/CT and
follow-up
99 85
11C-choline PET Bone marrow –
cellularity
Kotzerke et al (2000) 23 Consensus decision using bone scintigraphy. 11C-choline
PET-matched bone scintigraphy for lesion detection
NA NA
Abbreviations: CT¼ computerised tomography; DWI¼diffusion-weighted imaging; MDP¼methylene diphosphonate; MRI¼ magnetic resonance imaging; PET¼positron
emission tomography; SPECT¼single-photon emission computerised tomography; STIR¼ short tau inversion recovery; SUV¼standardised uptake value;
18FDG¼
18F-
fluorodeoxyglucose.
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choline or disease-specific targets such as PSA require investiga-
tion as they provide high sensitivity for disease activity.
In imaging prostatic bone metastases and their response to
therapy, the heterogeneity of disease, patient selection bias and
studies that lack a histopathological gold standard, make evalua-
tion of the literature challenging. Further validation of imaging
biomarkers of metastatic bone disease would do best if guided by
consensus groups with the purpose of clearly defining objectives,
prioritising imaging modalities to be taken forward, unifying
‘gold standards’ for bone disease and coordinating mulicentre
prospective trials.
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